Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select... see more

TSX:GUD - Post Discussion

Knight Therapeutics Inc > Simple Takeaway - Distribution Scale
View:
Post by longrun86 on May 14, 2023 11:24am

Simple Takeaway - Distribution Scale

Hi folks,

Lots of moving parts in this business; however, my key takeaway is that the distribution network and supporting infrastructure is in place; however, Knight needs to push more volume through in order to get the economies of scale needed to generate sufficient operating income margins.

Simply, move more volume (at the right margin) through the existing network.

Management is providing guidance for 14% to 15% EBITDA margins; however, this target needs to evolve to be high teens.

I don't know how they view the market share of Knights products but it would be good to get some better insight around that. They did mention that the generic business is facing competition; however, I haven't been able to get a sense of whether or not they feel they are achieving the right levels of market share. Please comment if I have missed something.

We need some movement from the business development team this year. The market is undoubtedly providing opportunities given interest rates and credit tightening. Does anyone have any insight into M8 or others? Conceptually, loans previously done at mid-teen rates when interest rates were ultra low would now be priced at the high-teens to low 20's.

Best of luck,

LR

Comment by gudisgood on May 15, 2023 5:30am
Random notes about the margins and the pipeline... In the Q4/21 earnings call Samira said they're happy with the mid-teen EBITDA margins "for now" which to me implies the expectation is to go higher than that along with scale. In the latest earnings call she also said they've expanded the pipeline "dramatically." I assume the innovative products in the pipeline will ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities